$BDPT

BioAdaptives, Inc. (BDPT) announced the first commercial orders for XcellaraHeart will ship next week, marking the launch of its Xcellara cellular wellness platform. The company also outlined progress in its capital restructuring, including the retirement of major debt and 43.25M insider shares. XcellaraResilience is scheduled for an October launch, with four additional formulations in development. The company appointed Michael Bisping as a brand ambassador for its MyndSystem platform.

BioAdaptives, Inc. (OTCID:BDPT) said its CEO James Keener converted preferred stock into common stock to raise public float by 43.25 million shares, then voluntarily canceled and retired those shares to avoid long-term overhang. The company also reported lender lock-up and leak-out agreements and an all-stock executive pay structure as it prepares the XcellaraHeart launch.

BioAdaptives Inc. (OTC:BDPT) said it launched and opened pre-orders for XcellaraHeart, a daily cardiovascular supplement in its Xcellara cellular wellness platform. The company cited an IRB-approved randomized, double-blind, placebo-controlled human trial showing a 268.8% average increase in circulating HSPCs after four weeks with no adverse effects across 20+ blood parameters. Pre-orders open Aug 12, 2026, first shipments Aug 26, 2026; price $159.95 per bottle.

BioAdaptives, Inc. (OTCID:BDPT) said it launched and opened pre-orders for XcellaraHeart, a daily cardiovascular supplement under its Xcellara cellular wellness platform. The company cites an IRB-approved randomized, double-blind, placebo-controlled trial reporting a 268.8% average rise in circulating stem/progenitor cells after 4 weeks, with no adverse effects reported.

BioAdaptives (US OTC: BDPT) said it will open commercial ordering for its XcellaraHeart cellular wellness formula later this week, as it shifts to direct-to-consumer e-commerce. The company linked the rollout to retiring its largest outstanding convertible debt to improve its capital structure. It plans three more Xcellara products in 2026 and will release a scientific evidence dossier on Aug. 4.

BioAdaptives, Inc. (OTCID:BDPT) said it retired its largest convertible commercial investor debt, removing the related equity overhang and reducing expected dilution from future conversions. The company linked the transaction to its August launch of XcellaraHeart and said it will focus on execution and revenue growth.

BioAdaptives (USOTC:BDPT) said its manufacturing and logistics preparations are complete for the next-month commercial launch of its MyndSystem and Xcellara wellness platforms. The company cited standardized raw-material sourcing and GMP-compliant manufacturing partnerships. MyndSystem targets cognitive wellness, while Xcellara targets cellular wellness. No revenue or orders were provided.

Regen Dog Chews are crafted to the highest quality standards, recommended by veterinarians and proven safe with no adverse effects reported in clinical trials Regen Dog Chews are crafted to the highest quality standards, recommended by veterinarians and proven safe with no adverse effects ...

LAS VEGAS, May 28, 2025 ( GLOBE NEWSWIRE ) -- via IBN -- BioAdaptives, Inc. BDPT, through its pets division PawPa™, a leader in premium pet wellness, proudly announces the remarkable stem cell benefits of its flagship product, Regen Dog Chews, validated through rigorous clinical testing and the ...